These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28545850)

  • 1. Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications.
    Nijst P; Verbrugge FH; Martens P; Dupont M; Tang WHW; Mullens W
    Int J Cardiol; 2017 Sep; 243():318-325. PubMed ID: 28545850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrarenal Flow Alterations During Transition From Euvolemia to Intravascular Volume Expansion in Heart Failure Patients.
    Nijst P; Martens P; Dupont M; Tang WHW; Mullens W
    JACC Heart Fail; 2017 Sep; 5(9):672-681. PubMed ID: 28711449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
    Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
    Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
    Verbrugge FH; Dupont M; Bertrand PB; Nijst P; Penders J; Dens J; Verhaert D; Vandervoort P; Tang WH; Mullens W
    Acta Cardiol; 2015 Jun; 70(3):265-73. PubMed ID: 26226699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure: Are There Differences? A Pilot Study.
    Miller WL; Mullan BP
    JACC Heart Fail; 2016 Jun; 4(6):453-9. PubMed ID: 26970830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction.
    Nijst P; Martens P; Verbrugge FH; Dupont M; Tang WHW; Mullens W
    J Cardiovasc Transl Res; 2020 Aug; 13(4):519-527. PubMed ID: 32100209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.
    Verbrugge FH; Martens P; Boonen L; Nijst P; Verhaert D; Noyens P; De Vusser P; Dupont M; Tang WHW; Mullens W
    Acta Cardiol; 2018 Aug; 73(4):335-341. PubMed ID: 28971753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Mullens W
    Am J Cardiol; 2017 Jul; 120(2):267-273. PubMed ID: 28532770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
    Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
    Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function and natriuresis-guided diuretic therapy - a pre-specified analysis from the PUSH-AHF trial.
    Damman K; Beldhuis IE; van der Meer P; Krikken JA; Coster JE; Nieuwland W; van Veldhuisen DJ; Voors AA; Ter Maaten JM
    Eur J Heart Fail; 2024 Jun; 26(6):1347-1357. PubMed ID: 38734982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.
    Testani JM; Hanberg JS; Cheng S; Rao V; Onyebeke C; Laur O; Kula A; Chen M; Wilson FP; Darlington A; Bellumkonda L; Jacoby D; Tang WH; Parikh CR
    Circ Heart Fail; 2016 Jan; 9(1):e002370. PubMed ID: 26721915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Ter Maaten JM; Rao VS; Hanberg JS; Perry Wilson F; Bellumkonda L; Assefa M; Sam Broughton J; D'Ambrosi J; Wilson Tang WH; Damman K; Voors AA; Ellison DH; Testani JM
    Eur J Heart Fail; 2017 Aug; 19(8):1014-1022. PubMed ID: 28105769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.